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NUAK1 (NUAK family SnF1-like kinase-1) and NUAK2 protein
kinases are activated by the LKB1 tumour suppressor and have
been implicated in regulating multiple processes such as cell
survival, senescence, adhesion and polarity. In the present paper
we present evidence that expression of NUAK1 is controlled
by CDK (cyclin-dependent kinase), PLK (Polo kinase) and the
SCFβTrCP (Skp, Cullin and F-boxβTrCP) E3 ubiquitin ligase complex.
Our data indicate that CDK phosphorylates NUAK1 at Ser445,
triggering binding to PLK, which subsequently phosphorylates
NUAK1 at two conserved non-catalytic serine residues (Ser476 and
Ser480). This induces binding of NUAK1 to βTrCP, the substrate-
recognition subunit of the SCFβTrCP E3 ligase, resulting in NUAK1
becoming ubiquitylated and degraded. We also show that NUAK1
and PLK1 are reciprocally controlled in the cell cycle. In G2–M-
phase, when PLK1 is most active, NUAK1 levels are low and
vice versa in S-phase, when PLK1 expression is low, NUAK1 is
more highly expressed. Moreover, NUAK1 inhibitors (WZ4003 or
HTH-01-015) suppress proliferation by reducing the population
of cells in S-phase and mitosis, an effect that can be rescued by
overexpression of a NUAK1 mutant in which Ser476 and Ser480
are mutated to alanine. Finally, previous work has suggested that
NUAK1 phosphorylates and inhibits PP1βMYPT1 (where PP1 is
protein phosphatase 1) and that a major role for the PP1βMYPT1
complex is to inhibit PLK1 by dephosphorylating its T-loop
(Thr210). We demonstrate that activation of NUAK1 leads to a
striking increase in phosphorylation of PLK1 at Thr210, an effect
that is suppressed by NUAK1 inhibitors. Our data link NUAK1
to important cell-cycle signalling components (CDK, PLK and
SCFβTrCP) and suggest that NUAK1 plays a role in stimulating
S-phase, as well as PLK1 activity via its ability to regulate the
PP1βMYPT1 phosphatase.
Key words: AMP-activated protein kinase (AMPK), AMPK-
related kinase 5 (ARK5), cell cycle, degron, mitosis, Polo kinase
(PLK) ubiquitylation.
INTRODUCTION
NUAK1 [NUAK family SnF1-like kinase-1; also known as
ARK5 (AMPK-related kinase 5)] and the closely related NUAK2
[SNARK (SNF1/AMP kinase-related kinase)] belong to the
AMPK (AMP-activated protein kinase) family of protein kinases
and are phosphorylated and activated by the LKB1 (liver kinase
B1) tumour suppressor protein kinase [1,2]. NUAK isoforms
are widely expressed and possess an N-terminal kinase domain
(residues 55–306, NUAK1), followed by a non-catalytic C-
terminal region (residues 307–661, NUAK1) [2]. LKB1 activates
NUAK isoforms by phosphorylating the kinase domain T-loop
residue (Thr211-NUAK1).
Previous work has indicated that NUAK isoforms play roles
in a number of processes including controlling embryonic
development [3,4], cell adhesion [5,6], senescence [7], neuronal
polarity and axon branching [8]. Other work points towards roles
of NUAK isoforms in regulating cell division, through its ability
to stimulate proliferation [9], promote invasion of cancer cells
[10–12] and function as a survival factor in Myc-driven tumours
[13]. Despite these studies, relatively little is known about how
NUAK isoforms are regulated and function. To date only a single
substrate, namely the MYPT1 subunit of the PP1βMYPT1 (where
PP1 is protein phosphatase 1) myosin phosphatase complex, has
been reported, whose phosphorylation is reduced in NUAK1-
knockout cells [6]. NUAK1 and NUAK2 phosphorylate MYPT1
at three conserved residues (Ser445, Ser472 and Ser910) in response to
conditions that induce cell detachment [6]. This phosphorylation
triggers binding of MYPT1 to 14-3-3 isoforms, thereby inhibiting
dephosphorylation of the myosin light chain by PP1βMYPT1 [6].
NUAK1 and NUAK2 associate with the PP1βMYPT1 via a set
of three highly conserved GILK motifs that bind directly to a
regulatory pocket on the surface of the PP1β catalytic subunit
[6].
Previous work has also revealed that PP1βMYPT1 acts to
inactivate PLK1 by dephosphorylating the T-loop Thr210 residue,
thereby controlling mitosis [14]. The ability of PLK1 to interact
with PP1βMYPT1 is dependent upon phosphorylation of MYPT1
at Ser473 by CDK1 (cyclin-dependent kinase 1), which creates a
docking site recognized by the Polo-box domains of PLK1 (Polo
kinase 1) [14]. Interestingly, Ser473 lies immediately adjacent to
the NUAK1 phosphorylation site (Ser472) that controls 14-3-3
binding. This therefore suggests that phosphorylation of MYPT1
by NUAK1 and 14-3-3 binding could directly interfere with the
ability of PP1βMYPT1 to interact with and hence dephosphorylate
PLK1.
Abbreviations: AMPK, AMP-activated protein kinase; CDK, cyclin-dependent kinase; CK1, casein kinase 1; Cul1, cullin 1; DMEM, Dulbecco’s modified
Eagle’s medium; DTB, double thymidine block; Emi1, early mitotic inhibitor 1; GST, glutathione transferase; HA, haemagglutinin; HEK, human embryonic
kidney; HRP, horseradish peroxidase; IKK, inhibitor of nuclear factor κB kinase; MEF, mouse embryonic fibroblast; LKB1, liver kinase B1; NEM, N-
ethylmaleimide; NUAK, NUAK family SnF1-like kinase; PEI, polyethylenimine; PI, propidium iodide; PLK1, Polo kinase 1; PP1, protein phosphatase 1;
SCFβTrCP, Skp, Cullin and F-boxβTrCP; SKP1, S-phase kinase-associated protein 1; Wee1, WEE1 G2 checkpoint kinase; WT, wild-type; XIC, extracted ion
chromatogram analysis.
1 Correspondence may be addressed to either of these authors (s.y.banerjee@dundee.ac.uk or d.r.alessi@dundee.ac.uk).
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In the present study we provide evidence that NUAK1 is
phosphorylated by PLK at two serine residues (Ser476 and Ser480)
that lie within a conserved ESGYYS phosphodegron motif
located in the C-terminal non-catalytic domain of NUAK1.
This phosphorylation triggers interaction with the SCFβTrCP (Skp,
Cullin and F-boxβTrCP) E3 ubiquitin ligase complex, leading to
polyubiquitylation and degradation of NUAK1. We demonstrate
that the levels of NUAK1 are low in the G2–M-phase of the
cell cycle when PLK1 is most active and high in the S-phase
when PLK1 expression is low. We also provide pharmacological
evidence that NUAK1 controls proliferation by regulating the
population of cells in S-phase and mitosis. Lastly, consistent with
NUAK1 inhibiting PP1βMYPT1 and PP1βMYPT1 acting on PLK1, we
demonstrate that cell detachment that promotes phosphorylation
and inhibition of PP1βMYPT1 by NUAK1 markedly enhances the T-
loop phosphorylation of PLK1. The present study provides further
insights into the biological regulation of the NUAK isoforms
and highlights the remarkable interplay that exists between PLK,
NUAK1, PP1βMYPT1 and SCFβTrCP signalling components.
MATERIALS AND METHODS
Materials
[γ 32P]ATP was from PerkinElmer. Protein G–Sepharose,
glutathione–Sepharose and the ECL kit were from GE Healthcare.
Sakamototide substrate peptide [ALNRTSSDSALHRRR] was
used for endogenous NUAK1 activity assay as described
previously [6]. P81 phosphocellulose paper was from
Whatman. The CellTiter 96® AQueous Non-Radioactive Cell
Proliferation Assay kit and sequencing-grade trypsin were from
Promega. RNase A and paraformaldehyde 4% solution were
purchased from Affymetrix. Novex 4–12% polyacrylamide
Bis-Tris gels, LDS Sample Buffer, PBS/EDTA-based Cell
Dissociation Buffer, hygromycin and other tissue culture
reagents were from Life Technologies. Calyculin A was
purchased from Cell Signalling Technology. Instant Coomassie
Blue stain was from Expedeon. PEI (polyethyleneimine)was
from Polysciences and 1 M magnesium acetate solution was
from Fluka. Anti-HA (haemagglutinin)–agarose, anti-FLAG–
agarose, DMSO, PI (propidium iodide), BSA, L-glutathione
reduced, Nonidet P40, thymidine, NEM (N-ethylmaleimide)
and benzamidine were from Sigma–Aldrich. PMSF was from
Melford. The International Centre for Protein Kinase Profiling
(http://www.kinase-screen.mrc.ac.uk) supplied MLN-4924, all
of the small molecule protein kinase inhibitors used in the
present study and purified GST (glutathione transferase) lambda
phosphatase.
Antibodies
The following antibodies were raised in sheep and affinity
purified on the appropriate antigen: anti-MYPT1 [human
MBP (myelin basic protein)–MYPT1 residues 714–1005,
S662B, first bleed], anti-MYPT1 phospho-Ser445 (residues
437–452 of mouse, RLGLRKTGS*YGALAEI, S508C, first
bleed), anti-MYPT1 phospho-Ser472 (residues 466–478 of
mouse, GVMRSAS*SPRLSS, S509C, second bleed), anti-
PP1β (residues 316–327 of human PP1β, TPPRTANPPKKR,
S383B, third bleed), anti-LKB1 (full-length mouse LKB1,
S170D, second bleed) and anti-NUAK1 (human His–NUAK1,
S628B, second bleed). The commercial antibodies used in the
present study were anti-βTrCP (catalogue number 4394; Cell
Signaling Technology), anti-β-tubulin (catalogue number 2128;
Cell Signaling Technology), anti-PLK1 (catalogue number 4513;
Cell Signaling Technology), anti-PLK1 Thr210 (catalogue number
55840; BD Biosciences), anti-cyclin B1 (catalogue number 4135;
Cell Signaling Technology), anti-(cyclin A) (catalogue number
4656; Cell Signaling Technology), anti-GAPDH (glyceraldehyde-
3-phosphate dehydrogenase; catalogue number ab8245; Abcam),
anti-SIK2 (salt-inducible kinase 2; catalogue number 6919;
Cell Signaling Technology), anti-phosphoH3 Ser10 (catalogue
number 3377; Cell Signaling Technology), anti-H3 histone
(catalogue number 4499; Cell Signaling Technology), anti-
ubiquitin (ZO458; Dako), anti-(phosphohistone H3–Alexa Fluor®
488) (catalogue number 9708; Cell Signaling Technology), anti-
(FLAG peroxidase) (A8592; Sigma) and anti-(HA peroxidase)
(3F10) (12013819001; Roche). HRP (horseradish peroxidase)-
conjugated secondary antibodies (1:2500 dilution) were obtained
from Thermo Scientific and HRP-coupled light chain-specific
secondary antibodies (1:10000 dilution) were purchased from
Jackson Immuno Research.
General methods
All recombinant DNA procedures, electrophoresis, tissue culture,
immunoblotting and immunoprecipitations were performed using
standard protocols. All mutagenesis was performed using the
QuikChange® site-directed mutagenesis method (Stratagene)
with KOD polymerase (Novagen). DNA constructs were purified
from Escherichia coli DH5α cells using QIAGEN maxi-prep kits
according to the manufacturer’s protocol. All DNA constructs
were verified by DNA sequencing, which was performed by
the Sequencing Service (MRC Protein Phosphorylation Unit,
College of Life Sciences, University of Dundee, Dundee,
U.K.; http://www.dnaseq.co.uk), using DYEnamic ET terminator
chemistry (GE Healthcare) on Applied Biosystems automated
DNA sequencers. Cell proliferation assay was carried out using
the CellTiter 96® AQueous Non-Radioactive Cell Proliferation
Assay kit as described previously [15].
Cell culture, treatments and cell lysis
U2OS and HEK (human embryonic kidney)-293 cells were
cultured in DMEM (Dulbecco’s modified Eagle’s medium)
supplemented with 10% FBS, 2 mM glutamine and 1×
antibacterial/antimycotic solution. βTrCP1+ / + and βTrCP1− / −
MEFs (mouse embryonic fibroblasts) were kindly provided
by Professor Keiichi Nakayama (Kyushu University, Fukuoka,
Japan) and were cultured in DMEM supplemented with
10% (v/v) FBS, 2 mM glutamine, 1× antibacterial/antimycotic
solution, 1% (v/v) non-essential amino acids and 1% (v/v)
sodium pyruvate. Transient transfections of HEK-293 cells
were carried out using PEI. U2OS Flp/In cells were kindly
provided by Professor John Rouse (University of Dundee,
Dundee, U.K.) and stable transfections were carried out in the
cells following a standard protocol (Invitrogen). Post stable
transfection, the U2OS Flp/In cells were selected and cultured in
DMEM supplemented with 10% (v/v) FBS, 2 mM glutamine, 1×
antibacterial/antimycotic solution and 100 μg/ml hygromycin.
Inhibitor treatments were carried out by treating the cells with
various concentrations of the inhibitors as indicated in the
Figure legends. The inhibitors were dissolved in DMSO and
the total concentration of DMSO in the culture medium never
exceeded 1%. Cells were lysed in lysis buffer containing 50 mM
Tris/HCl (pH 7.5), 1 mM EGTA, 1 mM EDTA, 1%Triton X-100,
50 mM NaF, 10 mM sodium 2-glycerophosphate, 5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 0.27 M sucrose,
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1 mM benzamidine (added before lysis), 1 mM PMSF (added
before lysis) and 0.1% 2-mercaptoethanol (added before lysis).
To observe ubiquitylation in immunoblotting, cells were lysed in
lysis buffer containing 20 mM NEM minus any reducing agent.
Lysates were clarified by centrifugation at 16000 g for 15 min
at 4 ◦C and either used for further experiments or snap frozen
in liquid nitrogen and stored at − 80 ◦C. Protein estimation was
carried out using Bradford method with BSA as a standard.
Lambda phosphatase assay
Endogenous NUAK1 was immunoprecipitated from 20 mg
of U2OS cells treated with 50 nM calyculin A. NUAK1
immunoprecipitates were incubated with either 10 μg of active
GST-lambda phosphatase or 50 mM EDTA-inactivated 10 μg
of GST-lambda phosphatase in a reaction volume of 50 μl
consisting of 50 mM Tris/HCl (pH 7.5), 1 mM MnCl2 and 0.1%
2-mercaptoethanol. Assays were incubated at 30 ◦C for 30 min.
The beads were washed three times in 50 mM Tris/HCl (pH 7.5),
0.1 mM EGTA and 0.5 M NaCl followed by washing two times
in 50 mM Tris/HCl (pH 7.5) and 0.1 mM EGTA. Samples were
analysed by immunoblotting.
Identification of NUAK1-interacting proteins by MS and
development of extracted ion chromatogram for phosphopeptide
U2OS Flp/In empty (control) or with overexpression of HA–
NUAK1 were lysed and HA–NUAK1 was immunoprecipitated
from 35 mg of lysate. Proteomic mass fingerprint analysis was
carried out to identify potential interactors of NUAK1 as described
previously [6]. Results were searched against the SwissProt or IPI
human database using Mascot (http://www.matrixscience.com).
Peptide mass fingerprinting data analysis was performed using
OLMAT (http://www.proteinguru.com/MassSpec/OLMAT).
HA–NUAK1, with or without 50 nM calyculin A, and HA–
NUAK1 S476A + S480A were immunoprecipitated from U2OS
Flp/In cells expressing either the WT (wild-type) or the mutant
HA–NUAK1. The immunoprecipitates were resolved on a
polyacrylamide gel that was stained with Coomassie Blue.
Bands migrating with the expected molecular mass of HA–
NUAK1 were excised from the gel, digested with trypsin and
subjected to HPLC-MS/MS on an ABSciex QTrap 4000 mass
spectrometer using precursor ion scanning for − 79 Da [16].
XIC (extracted ion chromatogram analysis; where the total
signal intensity of the phosphopeptide was plotted on the y-
axis and retention time was plotted on the x-axis) of the Ser476-
and Ser480-containing phosphopeptide (R.ESGYYSSPER.S + 1P)
was obtained manually using Analyst software (ABSciex).
Similarly, HA–NUAK1, with or without 1 μM BI2536 treatment,
was analysed by LC-MS/MS on a Thermo LTQ-Orbitrap and XIC
data was obtained manually using Xcalibur software (Thermo).
Kinase assay
Endogenous NUAK1 was immunoprecipitated from 5 mg of
βTrCP1+ / + and βTrCP1− / − MEFs in triplicates. Radioactive
kinase assay was carried out using Sakamototide substrate peptide
and [γ 32P]ATP-Mg2 + as described previously [6]. The samples
were further subjected to immunoblotting to visualize the levels
of NUAK1.
Cell cycle synchronization
U2OS cells were synchronized in the cell cycle by either DTB
(double thymidine block)–release for G1–S or by DTB with a
RO-3306 release for G2–M–G1. U2OS cells were plated at 40%
confluency and treated with 2.5 mM thymidine for 16 h. Cells
were subsequently washed twice with PBS and fresh medium
was added and cells were released from block for 12 h. A
second 2.5 mM thymidine block was introduced for another 16 h.
Following the DTB, cells were washed three times with PBS, fresh
media was added, and cells were harvested for flow cytometry and
immunoblotting at various time points as mentioned in the Figure
legends. For G2–M–G1 synchronization, after the DTB, cells were
washed three times in PBS and released in fresh medium for 6 h.
After release, 10 μM RO-3306 was added to the cells for 20 h.
After DTB + RO-3306 treatment, cells were washed three times
in PBS, fresh medium was added, and cells were harvested for
flow cytometry and immunoblotting at various time points as
mentioned in the Figure legends.
Analysis of cell cycle by flow cytometry
U2OS cells were analysed for their respective cell cycle
phase distribution using flow cytometry. Post-inhibitor treatment,
cells were trypsinized, washed with PBS + 0.2% BSA and
resuspended in flow cytometry tubes. Cells were then fixed by
70% ice-cold ethanol and stored at − 20 ◦C until analysis. After
washing fixed cells once with PBS, RNase A (50 μg/ml) and PI
(50 μg/ml) were added to the cells and incubated in the dark at
room temperature (25 ◦C) for 20 min. The live cell populations
were then subjected to quantitative measurement of DNA content
by flow cytometry using a FACSCaliburTM (BD Biosciences)
and cell cycle distribution and the percentage of G2–S–G1 cells
determined by the Watson (pragmatic) modelling algorithm using
FlowJo software (Treestar).
Calculation of mitotic cells by flow cytometry
U2OS cells were analysed for their respective percentage of
mitotic cells using flow cytometry. The cell medium was collected,
centrifuged and the floating population of mitotic cells were
collected in flow cytometry tubes. The adherent cells were try-
psinized, washed with PBS + 0.2% BSA and resuspended in
the same flow cytometry tubes. Cells were then resuspended in
0.5 ml of 1% paraformaldehyde in PBS and incubated at 37 ◦C
for 15 min. Cells were washed with PBS/BSA and then fixed by
90% ice-cold methanol and stored at − 20 ◦C until analysis. After
washing fixed cells once with PBS, the cells were resuspended
in 500 μl of diluted anti-(phosphohistone H3–Alexa Fluor® 488)
(1:200 dilution) in PBS. Cells were incubated for 1 h at room
temperature. Cells were washed in PBS/BSA and resuspended in
staining buffer containing RNase A (50 μg/ml) and PI (50 μg/ml)
and incubated in the dark at room temperature for 20 min. The
cells were then subjected to quantitative measurement of DNA
content and Alexa Fluor® 488 intensity by flow cytometry using a
FACS Calibur (BD Biosciences). The percentage of mitotic cells
determined by the Watson (pragmatic) modelling algorithm using
FlowJo software (Treestar).
Calculation of mitotic cells by microscopy
U2OS cells were split and approximately equal number of cells
was loaded into a 12-well plate. To study the effect of NUAK1
inhibition for mitosis, bright-field imaging was carried out with or
without treatment with DMSO (control) or 10 μM of WZ4003,
3 μM HTH-01-015 or 10 μM of RO-3306 (control of mitotic
defect). Inhibitors were added to the cells before the start of the
imaging. The imaging was carried out under a Nikon Eclipse
Ti microscope using objective ×20 phase with images taken
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Figure 1 NUAK1 binds to βTrCP
(A) HA–NUAK1 was immunoprecipitated (IP) from U2OS Flp/In cells expressing empty vector (Cntl) or with overexpression of HA–NUAK1. The immunoprecipitates were resolved on a polyacrylamide
gel and was stained with Coomassic Blue. The gel was divided into the indicated pieces, and proteins in these pieces were identified by mass spectrometry. Previously published interactors ubiquitin
and USP9X were identified in band 7, MYPT1, MYPT2 and MBS85 were identified in band 8, PP1β in band 11, and NUAK1 in band 9. βTrCP1 and βTrCP2 was identified in band 10, whereas
SKP1 was identified in band 12. Mascot scores of the interactors are detailed in Supplementary Table S1 (http://www.biochemj.org/bj/461/bj4610233add.htm). (B) Overexpressed HA–NUAK1 was
immunoprecipitated from U2OS Flp/In cell lysate stably overexpressing HA–NUAK1 and subjected to immunoblotting with the indicated antibodies. U2OS Flp/In cell lysate expressing empty vector
was used as a negative control. (C) HEK-293 cells were transfected with expression plasmids for GST-tagged AMPK-related kinases. At 36 h after transfection cells were lysed and GST-tagged
proteins were immunoprecipitated from 5 mg of cell lysates. Immunoprecipitates were analysed by immunoblotting with indicated antibodies. MARK, MAP/microtubule affinity-regulating kinase.
every 1 min by a Photometrics cascade II CCD (charge-coupled
device) camera using Nikon NIS Elements software. All drug
treatments were collected under the same conditions using the
multi-point visiting stage facility. The experiments were carried
out in triplicate. The percentage of cells in the field forming
mitotic contractile rings over a period of 1000 min was manually
counted from three independent fields of view and the data were
plotted using GraphPad Prism software. Only those cells forming
mitotic contractile rings were included, i.e. those which eventually
completed successful mitosis and formed two daughter cells.
Statistical analysis
All experiments described in the present paper were performed at
least twice and similar results were obtained. Data were analysed
using Student’s t test or one-way ANOVA followed by multiple
pair-wise comparisons (*P < 0.05). Error bars indicate S.D.
RESULTS
Interaction of NUAK1 with components of the SCFβTrCP E3 ligase
complex
We employed mass spectrometry to identify proteins
that specifically immunoprecipitated with stably overex-
pressed NUAK1 in osteosarcoma-derived U2OS cells (Fig-
ure 1A). NUAK1 was expressed ∼20-fold higher than
endogenous NUAK1 in these experiments (Supplementary Figure
S1 at http://www.biochemj.org/bj/461/bj4610233add.htm). These
studies revealed that in addition to previously reported NUAK1
interactors USP9X [17] and PP1βMYPT1 complex components
[6], we also observed constituents of the SCFβTrCP E3 ubiquitin
ligase complex (Figures 1A and 1B, and Supplementary Table
S1 at http://www.biochemj.org/bj/461/bj4610233add.htm). Both
closely related βTrCP1 and βTrCP2 isoforms that function as the
F-box-containing substrate-recognition components of the SCF
E3 ubiquitin ligase complexes [18,19], as well as SKP1 (S-phase
kinase-associated protein 1) and Cul1 (cullin 1) subunits, were
associated with NUAK1 immunoprecipitates (Figures 1A and
1B). βTrCP co-purified with overexpressed NUAK1 and NUAK2,
but not with the eight other AMPK-related protein kinases tested
(Figure 1C).
Phosphorylation of NUAK1 at Ser476 and Ser480 control association
with βTrCP
Previous work has demonstrated that βTrCP isoforms possess
multiple WD40 motifs at their C-terminus, which fold into a
target-recognizing phosphate-binding pocket [20]. βTrCP binds
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Figure 2 NUAK1 degron requires phosphorylation to interact with βTrCP
(A) U2OS cells were treated with or without 50 nM calyculin A for 10 min and the cells were lysed and endogenous NUAK1 was immunoprecipitated (IP) from 15 mg of cell lysates. Immunoprecipitates
were analysed by immunoblotting with indicated antibodies. Pre-immune IgG was used as a control. (B) Endogenous NUAK1 was immunoprecipitated from U2OS cells treated with 50 nM calyculin
A for 30 min. The immunoprecipitates were subjected to lambda-phosphatase assay with or without prior inactivation of lambda-phosphatase with EDTA. The immunoprecipitates were washed
thoroughly and were analysed by immunoblotting with indicated antibodies. (C) HEK-293 cells were transfected with expression plasmids for the GST-tagged NUAK1 WT or NUAK1 3IL/KK mutant.
At 36 h post-transfection cells were lysed and GST-tagged proteins were immunoprecipitated from 5 mg of cell lysates. Immunoprecipitates (IP) were analysed by immunoblotting with the indicated
antibodies. (D) Alignment showing the conservation of the ESGYYS degron of NUAK1 and NUAK2 within vertebrate orthologues. The sequences of Homo sapiens, Mus musculus, Gallus gallus,
Xenopus tropicalisi, Anolis carolinensis and Danio rerio NUAK1 and NUAK2 are from the NCBI. There are two copies of NUAK1 in D. rerio: one on chr. 4 and another on chr. 25. Alignment was
performed using T-Coffee software and visualized using Jalview. (E) Alignment of the candidate phosphodegron sequence DSGxxS between NUAK1 and the canonical βTrCP-interacting target proteins
IkB, β-catenin, Wee1, Emi1, claspin and Bora. (F) HEK-293 cells were transfected with expression plasmids for the GST-tagged NUAK1 WT or indicated mutants and immunoprecipitations and
immunoblottings were carried out as in (C). (G) HA–NUAK1 with or without calyculin A treatment and HA–NUAK1 S476A + S480A were immunoprecipitated (IP) from U2OS Flp/In cells expressing
either the WT or the mutant HA–NUAK1. The immunoprecipitates were resolved on a polyacrylamide gel and stained with Coomassie Blue. After trypsin digestion and precursor ion scanning
( − 79 Da) on the QTrap 4000 an XIC analysis of the Ser476 and Ser480 containing phosphopeptide (R.ESGYYSSPER.S + 1P) was carried out. The m/z value corresponding to this phosphopeptide
was detected in NUAK1 WT (both DMSO- and calyculin A-treated), but not in the S476A + Ser480A mutant. In the calyculin A-treated cells, the m/z value corresponding to the Ser476- or Ser480
-containing phosphopeptide was found to possess a >6-fold higher signal intensity than DMSO treated (control) immunoprecipitate. (H) HEK-293 cells were transfected with expression plasmids
for the GST-tagged NUAK1 WT or indicated mutants and immunoprecipitations and immunoblotting was carried out as in (C).
to the target proteins after they are phosphorylated at two residues
located four amino acids apart within a phosphodegron motif.
Different target proteins are phosphorylated by different kinases,
e.g. IκB (inhibitor of nuclear factor κB) by IKKs (IκB kinases)
[21], β-catenin by GSK3β (glycogen synthase kinase 3β) and
CK1 (casein kinase 1) [22], and Wee1 (WEE1 G2 checkpoint
kinase) by PLK [23]. These phosphorylations recruit the SCFβTrCP
E3 ubiquitin ligase, resulting in the target becoming ubiquitylated
and degraded by the proteasome.
To investigate whether interaction between βTrCP isoforms
and NUAK1 is controlled by phosphorylation, we first treated
U2OS cells in the presence or absence of the protein
phosphatase inhibitor calyculin A [24] to see whether this
enhances phosphorylation of NUAK1 and hence binding to
βTrCP. This revealed that calyculin A within 30 min markedly
enhanced association of βTrCP isoforms to endogenous NUAK1
(Figure 2A). Consistent with the association of βTrCP with
NUAK1 being mediated through phosphorylation, treatment
of endogenous NUAK1 immunoprecipitates with lambda
phosphatase-induced dissociation of βTrCP isoforms (Figure 2B).
As mentioned in the Introduction section, NUAK1 interacts
with the PP1βMYPT1 myosin phosphatase [6]. To investigate
whether disruption of the binding of PP1βMYPT1 to NUAK1 might
also promote NUAK1 phosphorylation and hence interaction with
SCFβTrCP, we mutated the three GILK motifs in NUAK1 that
mediate PP1βMYPT1 phosphatase binding [6] and observed
that this significantly enhanced binding of βTrCP (Figure 2C).
To identify the residues on NUAK1 that mediate binding to
βTrCP, we employed mass spectrometry to map phosphoryla-
tion sites on WT NUAK1. We also mapped phosphorylation
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Figure 3 NUAK1 is protected from phosphorylation-mediated degradation upon SCFβTrCP inhibition
(A) U2OS cells stably expressing NUAK1 WT or S476A + S480A mutant were treated with 50 nM calyculin A over the indicated periods of time. The cell lysates were analysed by immunoblotting
with indicated antibodies. (B) Endogenous NUAK1 was immunoprecipitated (IP) from 1 mg of U2OS cell lysates treated with calyculin A (50 nM) and with or without MLN-4924 (3 μM) over the
indicated periods of time prior to lysis. Immunoblotting was carried out to detect NUAK1 levels in the immunoprecipitates. Pre-immune IgG was used as a control. (C) Endogenous NUAK1 was
immunoprecipitated from 1 mg of U2OS cell lysates treated with MLN-4924 (3 μM) over the indicated periods of time prior to lysis. Immunoprecipitates were analysed by immunoblotting with indicated
antibodies. (D) βTrCP1+ / + (WT) and βTrCP1− / − (knockout) MEFs were lysed and analysed by immunoblotting with the indicated antibodies. Endogenous NUAK1 was immunoprecipitated and
its activity was assayed in triplicates with pre-immune IgG as control. Results are means +− S.D.
sites on the non-PP1βMYPT1-binding NUAK1 mutant, as
the results presented in Figure 2(C) indicate that the
βTrCP-binding phosphorylation residues should be more
highly phosphorylated in this mutant than the WT. We
therefore searched for NUAK1 phosphorylation sites located
four residues apart that might constitute a βTrCP-binding
phosphodegron motif, which were enhanced by ablation of
the PP1βMYPT1-binding GILK motifs (Supplementary Figure
S2 at http://www.biochemj.org/bj/461/bj4610233add.htm). From
this analysis, a doubly phosphorylated peptide meeting these
criteria was identified, encompassing Ser476 and Ser480, that
the mass spectrometry data suggested comprised the sites of
phosphorylation. These residues also lie within an ESGYYS
motif (residues corresponding to Ser476 and Ser480 are underlined),
which is highly conserved between NUAK isoforms in all of the
species we have analysed (Figure 2D) and similar to most other
characterized βTrCP-binding phosphodegron motifs (Figure 2E)
[25].
Consistent with phosphorylation of Ser476 and Ser480 mediating
βTrCP binding, mutation of these residues to alanine abo-
lished βTrCP isoform binding to NUAK1 (Figure 2F). Binding to
βTrCP was also suppressed by mutation of the conserved adjacent
Gly477 and Tyr478 (Figures 2E and 2F). We also observed using a
quantitative mass spectrometry approach that 50 nM calyculin
A enhanced phosphorylation of Ser476 and Ser480 approximately
6-fold (Figure 2G), which is likely to account for increased
association of βTrCP with NUAK1 under these conditions
(Figure 2A).
Ser476 and Ser480 lie adjacent to one of the conserved
PP1βMYPT1-binding GILK motif 2 (residues 466–469), indicating
the potential for competition between βTrCP and PP1βMYPT1
binding to NUAK1 (Figure 2D). We observed that mutation of
Ser476 and Ser480 to alanine to ablate βTrCP binding markedly
enhanced association of NUAK1 to PP1βMYPT1 (Figure 2H).
Mutation of the GILK motif 2 (residues 466–469), that lies
nearby Ser476 and Ser480, had no impact on βTrCP binding,
but mutation of motif 1 (residues 399–402) or motif 3
(residues 523–526) or all three GILK motifs (3IL/KK) enhanced
βTrCP binding (Figure 2H, and Supplementary Figure S3 at
http://www.biochemj.org/bj/461/bj4610233add.htm).
Evidence that NUAK1 is targeted for degradation by the SCFβTrCP E3
ligase complex
To investigate whether the expression of NUAK1 was controlled
by the SCFβTrCP E3 ligase complex, we first treated U2OS
cells stably expressing WT NUAK1 with 50 nM calyculin A
to induce βTrCP binding. This revealed that following 3 h
of calyculin A treatment, the levels of WT NUAK1, but not
the non-βTrCP-binding NUAK1[S476A + S480A] mutant, were
markedly reduced (Figure 3A).
Treating cells with calyculin A to enhance NUAK1
phosphorylation induced significant degradation of endogenous
NUAK1 within a 2–4 h time frame (Figure 3B). This effect
of calyculin A was blocked by treating cells with the
specific MLN4924 inhibitor that inactivates SCF E3 ubiquitin
ligase complexes by suppressing NEDDylation of Cul-1 [26]
(Figure 3B). Treatments of cells with MLN-4924 resulted in
significant increase in the expression of endogenous NUAK1 at
the 4–24 h time points (Figure 3C). In contrast, MLN-4924 had no
effect on the levels of the MARK1 (MAP/microtubule affinity-
regulating kinase 1), an AMPK-related kinase (Figure 3C) that
does not interact with βTrCP (Figure 1C). Both endogenous and
overexpressed NUAK1 underwent significant polyubiquitylation
upon calyculin A treatment, which was reversed upon pre-
treating the cells with MLN-4924 (Supplementary Figure S4 at
http://www.biochemj.org/bj/461/bj4610233add.htm).
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Figure 4 PLK1 interacts with NUAK1 at the CDK priming Ser445 site and phosphorylates NUAK1 at Ser476 and Ser480 and targets it for phosphorylation-mediated
degradation
(A) U2OS cells stably expressing HA–NUAK1 were treated with the indicated inhibitors for 4 h with or without 50 nM calyculin A treatment. Cell lysates were subjected to immunoblotting with the
indicated antibodies. The inhibitors were used at 1 μM final except for MLN-4924 (3 μM), BI605906 (5 μM), WZ4003 (10 μM) and D4476 (30 μM). (B) Endogenous NUAK1 was immunoprecipitated
(IP) from 1 mg of U2OS cell lysates treated with calyculin A (50 nM) and with or without the indicated concentrations of BI2536 and GSK461364 over the indicated periods of time prior to lysis.
Immunoblotting was carried out to detect NUAK1 levels in the immunoprecipitates. Pre-immune IgG was used as a control. (C) U2OS cells stably expressing NUAK1 WT were treated with the
indicated inhibitors for 1 h. HA–NUAK1 was immunoprecipitated and analysed by immunoblotting with the indicated antibodies. (D) HA–NUAK1 with or without BI2536 (1 μM) treatment was
immunoprecipitated (IP) from U2OS Flp/In cells stably expressing HA–NUAK. XIC analysis of the Ser476- and Ser480-containing phosphopeptide (R.ESGYYSSPER.S + 1P) was carried out. The m/z
value corresponding to the Ser476- or Ser480-containing phosphopeptide was detected in both samples. In the BI253-treated cells, the m/z value corresponding to the Ser476- or Ser480-containing
phosphopeptide was found to possess a ∼3-fold-higher signal intensity than the control immunoprecipitate. (E) HEK-293 cells were transfected with expression plasmids for the HA-tagged NUAK1
WT or the indicated mutants. At 36 h post-transfection cells were lysed and HA-tagged proteins were immunoprecipitated from 1 mg of cell lysates. Immunoprecipitates (IP) were analysed by
immunoblotting with indicated antibodies. (F) HEK-293 cells were transfected with expression plasmids for the HA-tagged NUAK1 WT or S445A mutant. At 36 h post-transfection cells were lysed
and HA-tagged proteins were immunoprecipitated from 1 mg of cell lysates. Immunoprecipitates (IP) were analysed by immunoblotting with indicated antibodies. (G) HEK-293 cells transiently
overexpressing NUAK1 WT or the S445A mutant were treated with 50 nM calyculin A over the indicated periods of time. The cell lysates were analysed by immunoblotting with the indicated antibodies.
To obtain further evidence that βTrCP1 regulates NUAK1,
we investigated how knockout of the βTrCP1 isoform in
previously described MEF cells [27] impacted on endogenous
NUAK1 expression. These experiments revealed that NUAK1
was expressed at a ∼2-fold-higher expression in βTrCP1-
knockout cells (that still express βTrCP2) (Figure 3D).
Moreover, endogenous NUAK1 catalytic activity assessed after
an immunoprecipitation protein kinase activity assay, was also
enhanced ∼2-fold in βTrCP1-knockout cells (Figure 3D).
Evidence that Polo kinase phosphorylates Ser476 and Ser480
In an attempt to pinpoint the kinase that phosphorylates NUAK1
at Ser476 and Ser480, we investigated the effect of a variety of
selective protein kinase inhibitors known to target kinases that
phosphorylate βTrCP-binding phosphodegron motifs on other
targets. These included inhibitors of IKKs (BI605906), GSK3β
(CHIR99021), polo-kinases (BI2536 and GSK461364), CK1
(D4476), aurora kinase (VX680) and CDKs (roscovitine). We
also tested a number of selective inhibitors of major protein
kinase signalling systems namely ATM (ataxia telangiectasia
mutated; KU55933), DNA-PK (DNA-dependent protein kinase,
catalytic subunit; 401KuDOS), ATR (ataxia telangiectasia
and Rad3 related; ETP46464), mTOR (mammalian target
of rapamycin; AZD8055), PI3K (phosphoinositide 3-kinase;
GDC0941) and Akt (MK2206). This analysis strikingly revealed
that two structurally unrelated inhibitors of polo kinases
(PLK1, PLK2 and PLK3), namely BI2536 [28] or GSK461364
[29], prevented the calyculin A-mediated decrease in the
levels of overexpressed WT NUAK1 (Figure 4A). BI2536
(http://www.kinase-screen.mrc.ac.uk/screening-compounds/
341035) and GSK461364 (http://www.kinase-screen.mrc.ac.uk/
screening-compounds/224) are highly potent and specific
inhibitors of PLK1, PLK2 and PLK3, but not PLK4 [30]. Dose-
dependence analysis indicated that the lowest dose of BI2536
and GSK461364 that inhibited the degradation of NUAK1 was
1 μM and 3 μM respectively (Figure 4B), in accordance with
the reported cellular IC50 of these compounds [28,29]. Consistent
with PLK mediating phosphorylation of Ser476 and Ser480, we
found that BI2536 and GSK461364 inhibited binding of βTrCP
to overexpressed NUAK1 (Figure 4C). Mass spectrometry
analysis also revealed that treatment of U2OS cells with BI2536
inhibitor significantly suppressed phosphorylation of NUAK1 at
Ser476 and Ser480 (Figure 4D).
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Evidence that CDK phosphorylates NUAK1 at Ser445 to enable
docking of PLK
In addition to the PLK inhibitors, we found that the CDK inhibitor
roscovitine stabilized NUAK1 expression following calyculin A
treatment (Figure 4A). Many reported PLK1 substrates, such
as aurora A kinase [31,32] and the Wee1 kinase regulator of
mitotic entry [23], are primed for PLK1 phosphorylation by
prior phosphorylation at a serine–proline motifs by CDKs. This
creates a docking site recognized by a pair of conserved polo-
box regions of 30 amino acids at the C-terminus that operate
as substrate-recognition domains within the C-terminal domain
of PLK1 [33,34]. The finding that roscovitine inhibited NUAK1
degradation following calyculin A treatment suggests that the
ability of PLKs to phosphorylate Ser476/Ser480 is dependent upon
prior phosphorylation of NUAK1 by CDKs. Consistent with this,
PLK1 that co-immunoprecipitates with NUAK1 is dissociated,
along with βTrCP, upon treatment of cells with roscovitine
(Figure 4C).
To determine the potential CDK phosphorylation site(s) on
NUAK1 that induce PLK binding, we inspected the NUAK1 phos-
phorylation sites we have mapped (Supplementary Figure S2) for
potential phosphorylated residues lying within serine/threonine–
proline motifs. This revealed three sites meeting this criteria
namely Ser388, Ser445 and Ser455 (Supplementary Figure S2). Ser388
[35,36], Ser445 [37] and Ser455 [36,37] are located within the C-
terminal non-catalytic residues of NUAK1 and phosphorylation
of these sites have also been observed in previous global
phosphoproteomic studies. We also observed that phosphorylation
of these residues is increased in the non-PP1βMYPT1 NUAK1
mutant (Supplementary Figure S2). Ser388 and Ser445, as well as
the adjacent + 1 proline, are conserved in all of the species we
have analysed. In contrast, the + 1 proline residue next to Ser455 in
human NUAK1 is not conserved in many species including mice
and rats. Our data suggest that Ser445 comprises the critical CDK
phosphorylation site controlling PLK1 binding as mutation of
Ser445, but not Ser388 or Ser455, suppressed interaction of NUAK1
with βTrCP (Figure 4E) as well as PLK1 (Figure 4F). Further-
more, the NUAK1[S445A] mutant was not degraded following
treatment of cells with 50 nM calyculin A for 3 h (Figure 4G).
Evidence that PLK controls NUAK1 expression in the cell cycle
PLK1 activity peaks at late S- and G2–M-phase of the cell cycle
before declining in the G1- to early S-phase [38]. To investigate
whether PLK1 regulates NUAK1 expression in the cell cycle,
we synchronized U2OS cells in the G2 stage of the cell cycle
using the DTB and CDK1 inhibitor (RO3306) release protocol
[39]. Cells were then lysed at intervals over a 21-h period
and immunoblotted for NUAK1, PLK1 and other cell cycle
control markers (cyclin B1, cyclin A and phosphohistone H3
Ser10). Consistent with a role of PLK1 in targeting NUAK1 for
degradation, we observed low levels of NUAK1 during the G2–
M-phase (0–1 h time point), when PLK1 as well as cyclin A
and B1 were elevated (Figure 5A). Expression levels of NUAK1
remained low in early G1-phase (3–5 h), increased at the 5–7 h
time points and were maximal from the 9 h time point onwards
(early S-phase to asynchronous) when PLK1 levels are low.
We also studied whether association of βTrCP with NUAK1 in
G1-, S-, G2- and early G1-phase of the cell cycle. Synchronization
efficiency in these studies was ascertained using flow cytometry
and immunoblotting for cyclin A and PLK1 (Figure 5B). This
revealed that levels of NUAK1 and co-immunoprecipitating
βTrCP were highest at the S-phase of the cycle when PLK1
levels are low (Figure 5B). Levels of NUAK1 and co-
immunoprecipitating βTrCP were very low at G2-phase as well as
early and late G1-phase (Figure 5B). Although expression of PLK1
is low in S-phase, it has been shown to be very active especially
during DNA replication [40,41]. We also observed high PLK1
activity during S-phase as indicated by its Thr210 phosphorylation
(Figure 5A), which is likely to explain why interaction of NUAK1
with βTrCP is maximal at S-phase. It should also be noted that our
data do not rule out the possibility of PLK2 or PLK3 isoforms that
we have not investigated could also play a role in phosphorylating
NUAK1 at the S/G2-phase.
We also observed that ablation of Ser476 and Ser480 markedly
inhibited the reduction in NUAK1 levels observed at the G1-
and G2-phases in parallel studies (Figure 5C). We reproducibly
observed that expression of the NUAK1[S476A + S480A]
mutant was still moderately lowered at G1- and G2-phases
(Figure 5C), suggesting that an alternative mechanism not
involving phosphorylation of these residues may operate to lower
NUAK1 at these phases of the cell cycle. Sequence inspection
indicates that NUAK1 possesses a canonical KEN box motif
(KENDFAQ residues 373–379), which might trigger binding and
consequent Lys11-linked ubiquitylation and degradation via the
E3 ligase APC/C (anaphase-promoting complex/cyclosome) in
the cell cycle [42,43].
Evidence that NUAK1 promotes cell proliferation by triggering
mitosis
We next investigated the effect that inhibiting NUAK1 catalytic
activity had on the cell cycle by treating asynchronous U2OS cells
for 8 h with two structurally distinct and highly selective NUAK1
inhibitors termed WZ4003 and HTH-01-015 [15]. This revealed
that both WZ4003 and HTH-01-015, under conditions which
they inhibit phosphorylation of the NUAK1 substrate MYPT1,
induced a ∼50% reduction in the population of cells in S-phase
(Figure 6A).
We also studied the impact that inhibiting NUAK1 had on the
mitotic population of asynchronous U2OS cells over a 1000 min
time course. This revealed that both WZ4003 and HTH-01-015
inhibitors markedly restricted cells from entering into mitosis
to a similar extent as treatment as the RO3306 CDK1 inhibitor.
After 600 min, no mitotic cells were detected following WZ4003
and HTH-01-015 treatment (Figure 6B). This mitotic progression
defect could be a result of a defect in the highly regulated S-phase
or the DNA replication phase of the cell cycle where NUAK1
might be playing a vital role.
We also observed that U2OS cells overexpressing the
NUAK1[S476A + S480A] mutant proliferated at nearly 2-fold-
higher rates than U2OS cells expressing WT NUAK1 or control
cells not overexpressing NUAK1 (Figure 6C). We also found that
overexpression of the NUAK1[S476A + S480A] mutant in U2OS
cells induced a significant ∼30–50% increase in population of
mitotic cells compared with control U2OS cells that overexpress
WT NUAK1 (Figure 6D).
Evidence that NUAK1 regulates PLK1 T-loop phosphorylation
As discussed in the Introduction section, PP1βMYPT1 binds to and
inhibits PLK1 by dephosphorylating the T-loop residue (Thr210)
[14]. The ability PP1βMYPT1 to bind to and dephosphorylate and
hence inactivate PLK1 is dependent upon phosphorylation of
MYPT1 at Ser473 by the CDK1, which creates a binding site
for the PLK1 Polo-box domains [14]. As Ser473 lies adjacent to
the NUAK1 phosphorylation site (Ser472) that controls 14-3-3
binding [6], we decided to explore whether NUAK1 could indeed
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Figure 5 NUAK1 protein levels are controlled by SCFβTrCP and PLK in the cell cycle
(A) U2OS cells were synchronized in the G2 stage of the cell cycle by a DTB and release after 10 μM RO-3306 inhibitor treatment. Cells were lysed after every 2 h over 24 h. Lysates were subjected
to immunoblotting with the indicated antibodies. (B) U2OS cells were synchronized in either in the G1/S stage of the cell cycle by a DTB or in the G2 stage by a DTB and release (Rel) after 10 μM
RO-3306 inhibitor treatment. Cells were either collected or lysed after indicated times. Collected cells were subjected to quantitative measurement of DNA content (PI staining) by flow cytometry using
a FACSCaliburTM (BD Biosciences) and the percentage of G1–S–G2 cells were determined by the Watson (pragmatic) modelling algorithm using FlowJo software (Treestar). Endogenous NUAK1 was
immunoprecipitated from 30 mg of cell lysates and immunoblotting was carried out using the indicated antibodies. (C) U2OS Flp/In cells stably expressing HA–NUAK1 WT or S476A + S480A were
synchronized as in (B) and the cell lysates were subjected to immunoblotting using the indicated antibodies.
influence PLK1 T-loop phosphorylation. We treated HEK-293
cells with EDTA to induce cell dissociation, a condition that has
previously been shown to promote phosphorylation of MYPT1 by
NUAK1 [6]. Immunoblotting with phospho-specific antibodies
confirmed that EDTA treatment induced phosphorylation of
MYPT1 at Ser445 and Ser472 (Figure 7). Strikingly, we observed
that EDTA also induced a significant stimulation of PLK1
phosphorylation at Thr210 that was accompanied by marked
electrophoretic band shift in PLK1 protein. Treatment of cells with
the WZ4003 dual NUAK1/NUAK2 inhibitor prior to stimulation
with EDTA, inhibited phosphorylation of Thr210 as well as the
electrophoretic mobility shift of PLK1 protein (Figure 7).
DISCUSSION
Our data demonstrate that NUAK isoforms are novel substrates
for PLK1 and SCFβTrCP E3 ubiquitin ligase complex. Our findings
suggest that PLK by phosphorylating NUAK1 at Ser476 and
Ser480 triggers interaction with the SCFβTrCP complex resulting
in ubiquitylation and degradation of NUAK1. This model is
supported by NUAK1 expression being increased following
inhibition of PLK (with BI2536 or GSK461364), mutation of
Ser476/Ser480 or inhibition of the SCF complex (with MLN4924).
We also demonstrate that in phases of the cell cycle where
PLK1 is most active (G2–M), NUAK1 levels are low and
vice versa when PLK1 is less active (late G1 to S), NUAK1
expression increases. Ser476 and Ser480 are highly conserved
and located within the C-terminal domain of NUAK isoforms.
To our knowledge Ser476/Ser480 have not been previously been
documented (http://www.phosphosite.org/).
Phosphorylation of a number of other substrates by PLKs
also triggers SCFβTrCP binding thereby leading to ubiquitylation
and degradation of the target. These include the Bora-activating
subunit of the aurora A kinase [31,32], the Wee1 kinase regulator
of mitotic entry [23], the mitotic regulator Emi1 (early mitotic
inhibitor 1) [44,45], the DNA replication checkpoint regulator
claspin 1 [46,47], the Fanconi’s anaemia group ATP-dependent
RNA helicase FANCM (Fanconi’s anaemia complementation
group M) [48] and HSF1 (heat-shock transcription factor 1) [49].
The phosphodegron motif that PLK1 phosphorylates in these
proteins is similar to the ESGYYS motif encompassing Ser476 and
Ser480 in NUAK1 as well as the equivalent residues in NUAK2
isoforms (Figure 2E). This phosphodegron motif is not conserved
in any other LKB1-activated AMPK or AMPK-related kinases,
indicating that the polo kinase-mediated phosphorylation and
subsequent SCFβTrCP ubiquitylation is unique to NUAK isoforms.
Consistent with this we found that βTrCP only interacts with
NUAK1 and NUAK2, but not with the other eight LKB1-activated
AMPK family members investigated (Figure 1C).
For most PLK substrates, prior phosphorylation by a CDK
isoform within a serine/threonine–proline motif creates a docking
site that is recognized by a pair of C-terminal polo-box
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Figure 6 NUAK1 degradation is required for controlled mitotic progression
(A) U2OS cells treated with or without 10 μM of WZ4003 or 3 μM HTH-01015 and U2OS Flp/In cells stably expressing NUAK1 WT and NUAK1 S476A + S480A were fixed in ice-cold 70 % ethanol,
stained with PI and analysed for cell cycle distribution by flow cytometry (as described in the Materials and methods section). The percentage of S-phase cells were calculated between control
and inhibitor treated using GraphPad Prism. *P < 0.05. (B) U2OS cells were treated with or without DMSO (control) or 10 μM of WZ4003 or 3 μM HTH-01015 or 10 μM of RO-3306 (control of
mitotic defect). Mitotic cells were manually counted and plotted using GraphPad Prism software as elaborated in the Materials and methods section. (C) NUAK1 levels in U2OS Flp/In NUAK1 WT
and S476A + S480A (SS/AA) were compared using immunoblotting of the cell lysates. Proliferation rate between U2OS Flp/In NUAK1 WT and S476A + S480A (SS/AA) was compared over 5 days
using CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit. Data were represented as percentage of growth times the Day 0 counts. (D) U2OS Flp/In NUAK1 WT (with or without
10 μM of WZ4003 treatment) and S476A + S480A (SS/AA) cells were harvested by centrifugation, fixed in 1 % paraformaldehyde, permeabilized with 90 % ice-cold methanol and stained with
anti-phosphohistone H3–Alexa Fluor® 488 antibody to quantify the mitotic population. The data are represented as the percentage of mitotic population and graphs were developed using GraphPad
Prism. Results are means +− S.D. *P < 0.05.
domains [33,34,50]. Our finding that treatment of cells with
roscovitine suppresses binding of PLK1 to NUAK1 leading
to increased expression (Figures 4A and 4C), supports the
idea that CDK phosphorylation primes NUAK1 for PLK
phosphorylation. Inspection of the NUAK1 phosphorylation sites
(Supplementary Figure S2), led to the identification of Ser445
as the potential CDK phosphorylation site and PLK-binding
residue. This is likely to comprise the CDK phosphorylation
site as its mutation to alanine inhibits PLK1 and hence βTrCP
binding to NUAK1 as well as calyculin A-mediated degradation
(Figures 4E–4G).
NUAK isoforms possess three highly conserved GILK motifs
that interact directly with the PP1β subunit of the PP1βMYPT1
complex [6]. Our findings suggest that inhibiting binding of
NUAK1 to PP1βMYPT1 by ablating the GILK motifs significantly
enhances βTrCP binding to NUAK1 (Figure 2H). This suggests
that PP1βMYPT1 acts to dephosphorylate either the PLK1-binding
CDK-primed site (Ser445) on NUAK1 and/or the βTrCP-
binding residues (Ser476 to Ser480) (Figure 8). PLK1 has also
been reported to interact with PP1βMYPT1, which leads to
dephosphorylation of the PLK1 T-loop (Thr210) residue and
thereby PLK1 inactivation [14,51]. Binding of PLK1 to MYPT1
is triggered following phosphorylation of the MYPT1 subunit
by CDK1 at Ser473 [14]. Interestingly, one of the key NUAK1
phosphorylation sites on MYPT1, namely Ser472, lies adjacent to
Ser473 that controls PLK1 binding to MYPT1. Phosphorylation
of Ser472 triggers 14-3-3 isoforms binding to MYPT1 [6]. Our
data indicate that subjecting HEK-293 cells to a condition
that promotes endogenous NUAK1 to phosphorylate MYPT1,
namely EDTA-induced cell detachment, leads to increased Thr210
phosphorylation of PLK1. This is also accompanied by an
electrophoretic band shift, suggesting that stoichiometry of
phosphorylation is significant (Figure 7). This phosphorylation of
Thr210 as well as the electrophoretic mobility shift is inhibited by
treatment with the NUAK1/NUAK2 WZ4003 selective inhibitor.
These data support the notion that NUAK1 may indeed play a
critical role in modulating PLK1 activity through its ability to
phosphorylate MYPT1. In future work it would be interesting
to explore whether phosphorylation of MYPT1 by NUAK1
influences association of PLK1 with PP1βMYPT1 and whether 14-
3-3 binding is involved. It would also be important to analyse
whether the effects that NUAK1 inhibitors have on suppressing
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Figure 7 NUAK1 regulated PLK1 T-loop Thr210 phosphorylation
HEK-293 cells were treated in the absence (DMSO) or presence of 10 μM of WZ4003 over
8 h. Cell medium was then replaced with either normal DMEM ( − ) or EDTA/PBS-based cell
dissociation buffer ( + ) containing the same concentration of WZ4003 or DMSO that the cells
were previously incubated in. Cell detachment was induced with gentle tapping of the plates
followed by gentle centrifugation at 70 g for 3 min. Cells were rapidly lysed either by scraping
for ( − ) cells or by resuspending in lysis buffer for ( + ) cells and the lysates were subjected to
immunoblotting with the indicated antibodies. Results shown in the histogram are means +− S.D.
mitosis (Figure 6) and cell proliferation [15] are mediated through
their ability to induce dephosphorylation and hence inactivation
of PLK1.
Our data suggest that there is a remarkable interplay between
NUAK1, PP1βMYPT1, SCFβTrCP, PLK and CDK components
(Figure 8). Conditions that enhance the ability of NUAK to
phosphorylate MYPT1 will increase PLK1 activity, by inhibiting
its dephosphorylation by PP1βMYPT1 complex. However, once
PLK1 activity is increased, this should result in phosphorylation
of Ser476 and Ser480 of NUAK1, at least once CDKs are
activated. This would in turn promote SCFβTrCP binding and hence
result in ubiquitylation and degradation of NUAK1. Reduced
NUAK1 level and activity will result in increased activity of
PP1βMYPT1 complex,
,
which will then inhibit PLK1 by inducing
dephosphorylation of the T-loop of PLK1.
A recent study reports that the LKB1 pathway plays a role
in regulating the centrosome via NUAK1, PP1βMYPT1 and PLK1
[52]. Consistent with our hypothesis that inhibiting NUAK1
will lead to increased association of PP1βMYPT1 and PLK1, the
authors of that study observed that shRNA-mediated knockdown
of LKB1, that would be expected to inhibit NUAK1 activity,
promoted the association of MYPT1 and PLK1 [52]. However,
despite these data, the authors then go on to argue that NUAK1
promotes interaction of PLK1 and MYPT1 thereby inducing
dephosphorylation of PLK1 [52]. This conclusion is the opposite
of what we have observed (Figure 7), and is also not consistent
with the observation that shRNA knockdown of LKB1 promotes
association of MYPT1 with PLK1.
We also found that treatment of cells with structurally diverse
highly selective NUAK1 inhibitors (WZ4003 and HTH-01-015
[15]) reduced by ∼50% the population of cells in S-phase
and also inhibited cells entering mitosis to the same extent as
treatment with the RO3306 CDK1 inhibitor (Figures 6A and
6B). Overexpression of a NUAK1 mutant in which Ser476
Figure 8 Schematic representation of how NUAK1 expression is regulated by PLK and SCFβTrCP
NUAK1 interacts with and phosphorylates PP1βMYPT1 myosin phosphatase complex at Ser445 and Ser472, which promotes 14-3-3 binding. In the S/G2-phase of the cell cycle NUAK1 and MYPT1 are
primed by CDKs, which creates a docking site for PLK. PLK1 interacts with MYPT1 at Ser473 which leads to inactivation of PLK1 upon PP1βMYPT1-mediated dephosphorylation of Thr210 at the PLK1
activation loop. PLK docking on to NUAK1 at Ser445 leads to phosphorylation of NUAK1 at Ser476 and Ser480, which promotes interaction of NUAK1 with SCFβTrCP E3 ubiquitin ligase complex that
triggers ubiquitylation and degradation of NUAK1 in the G2/M-phase of the cell cycle. PP1βMYPT1 negatively regulates PLK–NUAK1 interaction by possibly dephosphorylating the CDK priming site
on NUAK1 and hence protecting NUAK1 from degradation. RBX1, ring-box 1, E3 ubiquitin protein ligase.
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and Ser480 are ablated also significantly accelerated cell
proliferation (Figure 6C). The finding that NUAK1 is controlled
by critical cell cycle regulators namely CDKs, PLK1 as well
as SCFβTrCP, that orchestrates ubiquitylation and degradation of
key cell cycle co-ordinators [19], further highlights the role
that NUAK1 is likely to play a major role in controlling cell
cycle. PP1βMYPT1 has also been implicated in mediating important
roles in the cell cycle, by dephosphorylating PLK1 as well as
other proteins predicted to regulate kinetochore, centrosomes
and central spindle [14,51]. Although NUAK1 is degraded in
the G2–M-phase of the cell cycle, we believe that NUAK1 is
playing a vital role in the S-phase and hence inhibition of NUAK1
leads to defects in S-phase which progressively leads to mitotic
defects as well. In future work it would fascinating to explore
in more depth the interplay between NUAKs, PLK1, PP1βMYPT1
and SCFβTrCP to better define the role that this system plays
in regulating cell proliferation. Both BI2536 and GSK461364
potently inhibit PLK2 and PLK3 as well [30], so although
we have primarily focused on PLK1 in the present study, in
future work it would be interesting to explore roles of the other
Polo kinase family members in regulating the phosphorylation
of NUAK1. It would also be interesting to explore whether
inhibiting or activating NUAK1/NUAK2 impacted on the T-loop
phosphorylation and hence activity of these other PLK isoforms. It
would also be important to identify the key substrates that NUAK1
phosphorylates other than MYPT1 to regulate the cell cycle.
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Figure S1 LI-COR quantitation of the overexpression of WT compared with
endogenous NUAK1 expression
The Western blot signals for endogenous and overexpressed NUAK1 in U2OS Flp/In stable cells
were quantified using LI-COR Odyssey technology. β-Tubulin was used as a loading control.
The background signal was subtracted and then the band intensity of overexpressed NUAK1 was
divided by the signal for the endogenous NUAK1 protein (in duplicates). Data are means+−S.D.
relative to the expression levels of the endogenous protein.
1 Correspondence may be addressed to either of these authors (s.y.banerjee@dundee.ac.uk or d.r.alessi@dundee.ac.uk).
c© The Authors Journal compilation c© 2014 Biochemical Society
S. Banerjee and others
Figure S2 Phosphorylation sites on NUAK1 WT and the 3IL/KK mutant
HEK-293 cells were transfected with HA–NUAK1 WT or a mutant with all three GILK motifs mutated to GKKK (3IL/KK). At 36 h after transfection cells were lysed and HA–NUAK1 was immunoprecipitated
from 20 mg of cell lysates. Immunoprecipitates (IP) were separated on a polyacrylamide gel that was stained with colloidal Coomassie Blue. NUAK1 bands were then in-gel digested with trypsin and
peptides were identified by LC-MS/MS on an ABSciex QTrap 4000 using precursor ion scanning for − 79 Da. Major peaks corresponding to identified phosphopeptides of NUAK1 WT (red) and
NUAK1 3IL/KK (blue) are labelled P1–P13. Possible phosphorylation sites in the identified peptides are underlined.
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Figure S3 Effects of single IL/KK mutants on NUAK1–βTrCP interactions
HEK-293 cells were transfected with expression plasmids for the HA-tagged NUAK1 WT or
indicated mutants. At 36 h post-transfection cells were lysed and HA-tagged proteins were
immunoprecipitated from 1 mg of cell lysates. Immunoprecipitates (IP) were analysed by
immunoblotting with the indicated antibodies.
Figure S4 Calyculin A promotes polyubiquitylation and degradation of endogenous and overexpressed NUAK1, which can be reversed by MLN-4924
(A) Endogenous NUAK1 was immunoprecipitated from 1 mg of U2OS cells (lysed in the presence of NEM) treated with calyculin A (50 nM) and with or without pre-treatment of MLN-4924 (3 μM)
over the indicated periods of time prior to lysis. MLN-4924 treatment was carried out for 30 min prior to calyculin A treatment. Immunoblotting was carried out to detect ubiquitin and NUAK1 levels
in the immunoprecipitates. Pre-immune IgG was used as a control. (B) U2OS Flp/In NUAK1 WT cells were transfected with expression plasmids for FLAG-tagged ubiquitin. At 36 h post-transfection
cells were treated with or without calyculin A (50 nM) for 15 min and with or without 30 min pre-treatment with MLN-4924 (3 μM) prior to lysis with lysis buffer containing 20 mM NEM. HA–NUAK1
was immunoprecipitated from 1 mg of cell lysates. Immunoprecipitates (IP) were analysed by immunoblotting with indicated antibodies.
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Table S1 NUAK1-interacting proteins identified by mass spectrometry
The gel pieces shown in Figure 1(A) of the main text were digested with trypsin and proteins were identified by Orbitrap mass spectrometry. The identified proteins of importance that were present
only in the NUAK1 immunoprecipitate (bands 7–12), but not in the control (bands 1–6), are listed. Mascot protein scores are shown.
Gel band Protein Symbol Mass (Da) Mascot score Peptides
7 Probable ubiquitin C-terminal hydrolase FAF-X USP9X 292720 3732 230
Ubiquitin UBB 18295 74 5
8 Myosin phosphatase regulatory subunit 1 (MYPT1) PPP1R12A 115610 1134 92
Myosin phosphatase regulatory subunit 2 (MYPT2) PPP1R12B 110793 348 20
Myosin-binding subunit 85 (MBS85) PPP1R12C 85286 207 19
9 NUAK family Snf1-like kinase 1 (BAIT) NUAK1 74772 5947 256
10 F-box/WD repeat containing protein 11 βTrCP2 61772 353 32
F-box/WD repeat containing protein 1A βTrCP1 66262 208 20
11 Serine/threonine protein phosphatase PP1β catalytic subunit PPP1CB 37961 970 35
12 14-3-3 protein epsilon YWHAE 29326 324 13
S-phase kinase associated protein 1 SKP1 18817 46 2
Ubiquitin UBB 18295 56 2
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